Corporate Profile

Daxor Corporation (Nasdaq: DXR) is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology enhances hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved multiple measures of patient outcomes. Daxor’s mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all.

Daxor Corporation
107 Meco Lane,
Oak Ridge, TN 37830
865-425-0555
daxor.com
info@daxor.com
Investor Relations
Bret Shapiro
CORE IR
377 Oak Street
Garden City, NY 11530
516-222-2560

 Stock Performance


 Management Team

Michael Feldschuh – CEO & President
Jonathan Feldschuh – Chief Scientific Officer
Kathryn A. Kornafel – VP Marketing & Commercial Development
Robert Michel – Chief Financial Officer
Jean Oertel – Sr. VP Commercialization & Customer Experience
Soren Thompson – VP Business Development

 Board of Directors

Michael Feldschuh – Director
Henry D. Cremisi, MD, FACP – Director
Jonathan Feldschuh – Chief Scientific Officer
Edward S. Feuer – Director
Joy Goudie, Esq. – Director
James A. Lombard – Director
Caleb DesRosiers – Director

 Recent Headlines